Northern Trust
MAZE

Northern Trust’s Maze Therapeutics MAZE Stock Holding History

Northern Trust’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.8M Buy
294,742
+83,360
+39% +$2.18M ﹤0.01% 2283
2026
Q1 		$6.31M Buy
211,382
+35,123
+20% +$1.55M ﹤0.01% 2338
2025
Q4 		$7.3M Sell
176,259
-631
-0.4% -$21.7K ﹤0.01% 2250
2025
Q3 		$4.59M Buy
176,890
+91,344
+107% +$1.54M ﹤0.01% 2548
2025
Q2 		$1.05M Buy
85,546
+14,708
+21% +$153K ﹤0.01% 3362
2025
Q1 		$780K Buy
+70,838
New +$853K ﹤0.01% 3384

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

Northern Trust's MAZE Position: Q2 2026 in Review

Northern Trust increased its Maze Therapeutics (MAZE) stake by 39% in Q2 2026, buying an estimated $2.18M and bringing the position to 294,742 shares worth $8.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2283.

Northern Trust first reported a position in MAZE in Q1 2025 and has held it in 6 quarters since. 162 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • Northern Trust held 294,742 shares of Maze Therapeutics worth $8.8M as of Q2 2026.
  • Northern Trust bought 83,360 Maze Therapeutics shares in Q2 2026, an estimated $2.18M.
  • Maze Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #2283 holding.
  • Northern Trust first reported a position in Maze Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 162 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.